BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on BioCryst Pharmaceuticals, with eight buy ratings and four holds. The average 12-month price target is $20.60, well above the stock’s recent price of $9.66.
• BioCryst reported quarterly EPS of $0.30, beating the $0.15 consensus estimate, while revenue rose 33.6% year over year to $218.25 million, above expectations.
• Institutional ownership is high at 85.88%, with several major investors increasing positions during the second quarter; however, the stock recently declined 4.1% and analysts expect a full-year loss.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.60.

A number of research analysts have weighed in on BCRX shares. Royal Bank Of Canada reduced their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Needham & Company LLC dropped their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Finally, Wedbush decreased their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday, August 6th.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $912,000. Moore Capital Management LP purchased a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at about $8,483,000. Northwestern Mutual Wealth Management Co. lifted its position in BioCryst Pharmaceuticals by 40.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 10,254 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 2,942 shares during the period. Hsbc Holdings PLC boosted its stake in BioCryst Pharmaceuticals by 247.1% during the second quarter. Hsbc Holdings PLC now owns 109,320 shares of the biotechnology company's stock worth $1,079,000 after acquiring an additional 77,821 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in BioCryst Pharmaceuticals by 197.2% during the second quarter. Wellington Management Group LLP now owns 293,925 shares of the biotechnology company's stock worth $2,939,000 after acquiring an additional 195,042 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 4.1%

NASDAQ:BCRX opened at $9.66 on Friday. The company has a 50-day moving average price of $9.61 and a 200-day moving average price of $8.93. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -6.44 and a beta of 0.55. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million for the quarter, compared to analysts' expectations of $183.28 million. During the same quarter in the previous year, the company earned $0.15 earnings per share. BioCryst Pharmaceuticals's quarterly revenue was up 33.6% on a year-over-year basis. Equities analysts forecast that BioCryst Pharmaceuticals will post -2.25 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source